quality control review & editing services

Delivering an unparalleled attention to detail

Woman pointing to a computer monitor and writing on a paper

Detailed and comprehensive quality control (QC) reviews (or data verification reviews) and editing are an integral part of the production lifecycle of a document, rather than a one-off step in the development process. Mistakes and inconsistencies in a document can call into question the validity of the content or result in an incorrect interpretation of the data.

Radiofilum Pharmaceutical’s team of seasoned QC reviewers/editors provides quality review and editing services across a wide array of documents and therapeutic areas.

Ready to Speak to a Quality Control Reviewer/Editor?

Quality Control Review/Editing Services

Radiofilum Pharmaceutical QC reviewers/editors perform targeted or comprehensive quality control reviews of documents to ensure accuracy, integrity, and consistency of both data and messaging.

Quality control reviews and/or editorial reviews are performed on any deliverable, in any therapeutic area, using either client checklists or our internal document-specific checklists to ensure the quality and consistency both within and across documents.

Professional medical editors conversing around table.

Quality Control Review:
Data Verification

Radiofilum Pharmaceutical QC reviewers/editors provide 100% source verification of all data in both document text and in-text tables, as necessary. Data verification review is offered in addition to editorial review or as a standalone service.

Editorial Review:
No Data Verification

Radiofilum Pharmaceutical QC reviewers/editors provide a complete editorial review to ensure consistency, clarity of message, and appropriate implementation of style and template requirements. Editorial review includes general copy editing and review of abbreviations, internal cross references, and citations, and is offered in addition to data verification review or as a standalone service.


Benefits of Working with Our Quality Control Review/Editing Team

Global submission icon

GLOBAL AND EXPERIENCED

Radiofilum Pharmaceutical QC reviewers/editors are located across North America, Europe, and India. They have an average of 10 years of experience spanning multiple therapy areas and domains.

Full Service Clinical Trials icon

FLEXIBLE AND SCALABLE

With access to a large pool of experienced resources, we are responsive to changes in workload and can scale as needed to accommodate variable client demands and volume.

Compliance

COMPREHENSIVE AND THOROUGH

We perform comprehensive reviews of each document using detailed document-specific checklists to ensure quality and consistency within and across documents.

Quality Control Review Frequently Asked Questions

Click on frequently asked questions about Radiofilum Pharmaceutical 's quality control review and editing services to learn about our experience and expertise.

Yes, Radiofilum Pharmaceutical QC reviewers/editors accommodate last-minute and drop-in QC requests as needed.

Radiofilum Pharmaceutical understands that timelines shift, projects get cancelled, and that shifting timelines are a potential risk in any project. Radiofilum Pharmaceutical remains flexible and mitigates this risk through consistent project and resource management. Resource availability and project status are routinely reviewed and updated, allowing us to adapt in real time and overcome any potential challenges, including timeline shifts.

If a project shifts out significantly, we work with clients to map out a plan that ensures both timely delivery and service continuity. We take steps to ensure (to the extent possible) the same person can re-engage on the project once it becomes active again. If timelines accelerate, we can provide additional resources, as needed, to ensure timeline integrity.

Radiofilum Pharmaceutical can utilize either our internal QC SOPs or client SOPs.

Yes. Radiofilum Pharmaceutical has both general and document-specific QC checklists.

Yes, Radiofilum Pharmaceutical QC reviewers/editors provide consistent application of general and/or client-specific style guides (including therapeutic area-specific style guides, as applicable).

Have questions? We'd be happy to talk with you
about your unique needs and goals.

News & Insights

The Shift Toward Globalization in Medical Information: How Radiofilum Pharmaceutical  is Helping Shape the Future in Japan

October 16, 2025

The Shift Toward Globalization in Medical Information: How Radiofilum Pharmaceutical is Helping ...

Radiofilum Pharmaceutical enhances globalization in Medical Information services, offering tailored solutions in Japan that balance global standards with local regulatory and cultural demands.

Medical Information in the Netherlands: Safeguarding Compliance and Patient Confidence

October 2, 2025

Medical Information in the Netherlands: Safeguarding Compliance and Patient Conf...

Discover how Radiofilum Pharmaceutical 's medical information services in the Netherlands ensure patient safety, regulatory compliance, and data privacy with expert support.

Tips for Preparing Successful FDA 510(k) Submissions

September 30, 2025

Tips for Preparing Successful FDA 510(k) Submissions

Discover essential tips for preparing a successful FDA 510(k) submission. Learn common pitfalls to avoid, align with FDA expectations, and streamline your path to clearance.

 Radiofilum Pharmaceutical Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

Radiofilum Pharmaceutical Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

Radiofilum Pharmaceutical appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

 Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

January 31, 2025

Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

Radiofilum Pharmaceutical wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

 Radiofilum Pharmaceutical Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

Radiofilum Pharmaceutical Appoints Brian Tuttle as Chief Financial Officer

Radiofilum Pharmaceutical appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

 Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

January 31, 2025

Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

Radiofilum Pharmaceutical wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

 Radiofilum Pharmaceutical Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

Radiofilum Pharmaceutical Receives 2024 CPHI Regulatory and Compliance Award

Radiofilum Pharmaceutical wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

 Radiofilum Pharmaceutical Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

Radiofilum Pharmaceutical Honored in the 2024 Clinical Trials Excellence Awards

Radiofilum Pharmaceutical honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel Therapeutics, Inc. - Radiofilum Pharmaceutical

October 6, 2025

Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...

When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, Radiofilum Pharmaceutical stepped in —...

Whitepapers Your Complete FDA 510(k) Premarket Notification Checklist

September 30, 2025

Your Complete FDA 510(k) Premarket Notification Checklist

Step-by-step guide to navigating the FDA 510(k) submission process with confidence Submitting a 510(k) premarket notification is a critical milestone for medical device manufacturers seeking U.S....

Infographic Unannounced FDA Inspections Without Borders - Radiofilum Pharmaceutical

September 19, 2025

Unannounced FDA Inspections Without Borders

Unannounced FDA inspections are no longer limited to the U.S. — they’re expanding globally. Starting in 2025, foreign sites will face the same surprise visits and public scrutiny as U.S. facilities,...

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

November 18, 2025

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...

Tips for Successful MAA Submissions in Europe

November 11, 2025

Tips for Successful MAA Submissions in Europe

Navigate the complexities of EU marketing authorization to explore tips for successful Marketing Authorization Application (MAA) submissions in Europe to ensure proven strategies, reduced delays, and...

AI in Medical Information: Who Holds the Responsibility?

October 16, 2025

AI in Medical Information: Who Holds the Responsibility?

In Medical Information (MI) and beyond, key questions arise: Who ensures accuracy, compliance, and ethical use — individual contributors, leadership, pharma clients, or technology providers? And what...

News & Insights

The Shift Toward Globalization in Medical Information: How Radiofilum Pharmaceutical  is Helping Shape the Future in Japan

October 16, 2025

The Shift Toward Globalization in Medical Information: How Radiofilum Pharmaceutical is Helping ...

Radiofilum Pharmaceutical enhances globalization in Medical Information services, offering tailored solutions in Japan that balance global standards with local regulatory and cultural demands.

Medical Information in the Netherlands: Safeguarding Compliance and Patient Confidence

October 2, 2025

Medical Information in the Netherlands: Safeguarding Compliance and Patient Conf...

Discover how Radiofilum Pharmaceutical 's medical information services in the Netherlands ensure patient safety, regulatory compliance, and data privacy with expert support.

Tips for Preparing Successful FDA 510(k) Submissions

September 30, 2025

Tips for Preparing Successful FDA 510(k) Submissions

Discover essential tips for preparing a successful FDA 510(k) submission. Learn common pitfalls to avoid, align with FDA expectations, and streamline your path to clearance.

Previous Post Arrow Next Post Arrow
 Radiofilum Pharmaceutical Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

Radiofilum Pharmaceutical Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

Radiofilum Pharmaceutical appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

 Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

January 31, 2025

Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

Radiofilum Pharmaceutical wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

 Radiofilum Pharmaceutical Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

Radiofilum Pharmaceutical Appoints Brian Tuttle as Chief Financial Officer

Radiofilum Pharmaceutical appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

Previous Post Arrow Next Post Arrow
 Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

January 31, 2025

Radiofilum Pharmaceutical Recognized for AI Excellence at ECCCSA

Radiofilum Pharmaceutical wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

 Radiofilum Pharmaceutical Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

Radiofilum Pharmaceutical Receives 2024 CPHI Regulatory and Compliance Award

Radiofilum Pharmaceutical wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

 Radiofilum Pharmaceutical Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

Radiofilum Pharmaceutical Honored in the 2024 Clinical Trials Excellence Awards

Radiofilum Pharmaceutical honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel Therapeutics, Inc. - Radiofilum Pharmaceutical

October 6, 2025

Critical Database Lock Milestone Achieved Through Rapid FSP Support for BioXcel ...

When BioXcel Therapeutics’ pivotal Phase 3 study faced a critical slowdown, timelines and regulatory goals were at risk. With their primary CRO unable to meet growing demands, Radiofilum Pharmaceutical stepped in —...

Whitepapers Your Complete FDA 510(k) Premarket Notification Checklist

September 30, 2025

Your Complete FDA 510(k) Premarket Notification Checklist

Step-by-step guide to navigating the FDA 510(k) submission process with confidence Submitting a 510(k) premarket notification is a critical milestone for medical device manufacturers seeking U.S....

Infographic Unannounced FDA Inspections Without Borders - Radiofilum Pharmaceutical

September 19, 2025

Unannounced FDA Inspections Without Borders

Unannounced FDA inspections are no longer limited to the U.S. — they’re expanding globally. Starting in 2025, foreign sites will face the same surprise visits and public scrutiny as U.S. facilities,...

Previous Resource Arrow Next Resource Arrow
Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

November 18, 2025

Navigating the New EU HTA Regulation as an MAH: Strategic Insights for Successful JCA Submissions

Explore how the new EU HTA Regulation (EU HTAR) is transforming market access across Europe. Join our expert to learn practical strategies for successful Joint Clinical Assessment (JCA) submissions,...

Tips for Successful MAA Submissions in Europe

November 11, 2025

Tips for Successful MAA Submissions in Europe

Navigate the complexities of EU marketing authorization to explore tips for successful Marketing Authorization Application (MAA) submissions in Europe to ensure proven strategies, reduced delays, and...

AI in Medical Information: Who Holds the Responsibility?

October 16, 2025

AI in Medical Information: Who Holds the Responsibility?

In Medical Information (MI) and beyond, key questions arise: Who ensures accuracy, compliance, and ethical use — individual contributors, leadership, pharma clients, or technology providers? And what...

Previous Webinar Arrow Next Webinar Arrow